Sign up to save your podcasts
Or
Share NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
View all episodes
By NEJM Group
4.4
120120 ratings
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
131 Listeners
Medicine and Science from The BMJ
40 Listeners
NEJM Journal Watch Podcasts: Clinical Conversations
56 Listeners
NEJM This Week
325 Listeners
JACC This Week
161 Listeners
JAMA Clinical Reviews
496 Listeners
Mayo Clinic Talks
281 Listeners
JAMA Medical News
90 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
138 Listeners
Leadership Conversations
5 Listeners
Core IM | Internal Medicine Podcast
1,095 Listeners
Curbside Consults
87 Listeners
Annals On Call Podcast
194 Listeners
The Clinical Problem Solvers
519 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
The Curious Clinicians
366 Listeners
Infectious Disease Puscast
82 Listeners
NEJM AI Grand Rounds
54 Listeners
Intention to Treat
31 Listeners
Not Otherwise Specified
45 Listeners